Q4 25 Cxbladder Volumes Rise and Key Metrics Improve

Q4 25 CXBLADDER VOLUMES RISE AND KEY METRICS IMPROVE Pacific Edge sees lift in number of US clinicians ordering Cxbladder and number of tests ordered per clinician DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces tests processed at its laboratories in Q4 25 improved 6.8% on the prior quarter (Q3 25), lifted by increased adoption in the US. Total laboratory throughput (TLT) in Q4 25 rose to 7,577 tests from 7,092 tests in Q3 25. Q4 25 US TLT was 6,490 tests up 11.7% from the 5,808 tests in Q3 25, lifted by an increase in the number of unique US ordering clinicians to 914 from 8661 in Q3 25 and an increase in the number of tests each US clinician orders to 7.1 from 6.71 in Q3 25. The US volume lift follows continuing incremental improvements in sales force efficiency, up to 406 tests per sales FTE from 379 tests in Q3 25, and a seasonal post-holiday rebound. The American Urological Association’s (AUA) February 2025 inclusion of Cxbladder Triage with a ‘Grade A’2 evidence rating in its new microhematuria guideline has changed our sales pitch to clinicians, medical policy makers and healthcare payers, and generated renewed interest in Cxbladder among the broader urology customer base. The longer-term impact of this change may take some time to affect the daily lab throughput figures, and as we await various coverage-related events, our commercial team will focus on profitability per sales resource in the wake of the guideline update before seeking to expand the size of the team. Further commentary on the implications of this guideline for Pacific Edge are detailed in the investor update released today. Q4 25 Asia Pacific TLT was 1,087 tests down 15% on the 1,284 tests in Q3 25, with the decrease partly reflecting a reduction in evaluation and clinical study volumes as we continue to focus on commercial testing volumes and see the impact of budgetary constraints within some Health New Zealand – Te Whatu Ora regions. Total volumes for the year to the end of March 2025 (FY 25) were down 11.5% to 28,894 tests from 32,633 in FY 24, with the fall reflecting the reduction in the sales force compared to the prior financial year in response to the uncertainty over Medicare coverage of Cxbladder. In addition to the commentary on the guideline, the Q4 25 investor update also provides: An overview of the new evidence demonstrating the clinical utility of Cxbladder Monitor in the surveillance for the recurrence of bladder cancer and the cost savings it delivers to healthcare payers. Our formal rebuttal of the evidentiary review of ‘Genetic Testing in Oncology: Specific Tests’ (L39365) Local Coverage Determination released on 9 January 2025. Advances in our clinical evidence generation program and how the AUA guideline inclusion has further validated the role our clinical science team plays in creating shareholder value. Released for an on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer. Investors: Dr Peter Meintjes Chief Executive Pacific Edge P: 022 032 1263 Media: Richard Inder The Project P: +64 21 645 643